SGLT-2 inhibitors are now considered one of the most important antidiabetic agents in T2DM and are particularly recommended for the treatment of patients with diabetes with cardiovascular and renal comorbidities or risks for these conditions due to their proven cardio–renal protective effect, regardless of the degree of diabetes control [24]. This evidence concerns the gene SLC5A2 and diabetes mellitus.